Samsung Biologics Q3 2026: Revenue Up 18.5% but Net Profit Down 21.2% as Margin Slips from 50.4% to 42.9%

Q3 revenue reached KRW 1.4903T (+18.5% YoY), operating profit KRW 640.1B (+1.0%) and net profit KRW 391.1B (-21.2%), with the operating margin falling from 50.4% to 42.9%. Growth came from full utilisation of Plants 1-4, the Plant 5 ramp and the first revenue contribution from Rockville, while three cost items landed at once. Management still raised full-year revenue growth guidance to 20% and holds USD 21.9B in cumulative binding CMO contracts.

On 21 October, Samsung Biologics (KRX: 207940) reported third-quarter 2026 results. Q3 revenue was KRW 1.4903T, up 18.5% year on year and 12.8% quarter on quarter; operating profit was KRW 640.1B, up just 1.0%; net profit was KRW 391.1B, down 21.2% year on year and 9.2% sequentially. For the first nine months, revenue reached KRW 4.0684T (+24.4%), operating profit KRW 1.8073T (+17.3%) and net profit KRW 1.291T (+11.2%).

The revenue-profit scissors: three cost items at once

Gross profit barely moved, from roughly KRW 736.0B to KRW 738.0B, which tells you capacity utilisation did not deteriorate. The pressure sat entirely below the gross line: the operating margin fell 7.5 percentage points to 42.9%. Management attributed this to three overlapping factors: incremental costs from process performance qualification (PPQ) batches as Plant 5 (180,000 L) ramps; initial operating costs at the Rockville, Maryland facility acquired in March, which contributed revenue for the first time this quarter while still filling capacity; and the translation effect of roughly 95% of revenue being denominated in US dollars. In addition, net non-operating income swung from +KRW 29.1B a year earlier to -KRW 108.1B, a KRW 137.2B deterioration that exceeded the entire year-on-year increase in operating profit (KRW 6.6B) and pushed pre-tax profit down 19.7% — the single largest reporting factor behind the net profit decline.

USD 21.9B in orders, full-year guidance raised to 20%

The commercial side kept expanding. Cumulative binding CMO contract value reached USD 21.9B at the end of Q3, up about 9.0% from USD 20.1B a year earlier. The company has 117 cumulative CMO projects and 184 CDO projects, versus 107 and 164 respectively at the end of 2025, and has obtained 496 cumulative regulatory approvals for CMO products. Citing full utilisation of Plants 1-4, revenue contribution from Plant 5 PPQ batches and stabilising commercial production at Rockville, management raised 2026 full-year revenue growth guidance to 20% from a prior range of 15-20%, implying roughly KRW 5.47T. President and CEO John Rim framed the environment simply: as global pipelines become more diverse and supply requirements more complex, consistent execution across manufacturing programmes matters more than ever.

One detail deserves attention: the gap between order growth and revenue growth. Cumulative contract value rose 9.0% while quarterly revenue rose 18.5%, which means the quarter was driven more by execution on existing contracts and new capacity coming online than by fresh order intake. For a business model built on full utilisation and long-term agreements that is not abnormal, but it does mean 2027 revenue elasticity depends on signing new contracts against the remaining Plant 5 capacity and the unused capacity at Rockville — which the company confirms is still under negotiation.

Capacity roadmap: from 845,000 L to 1,385,000 L

Total global biologics capacity stands at 845,000 L: 785,000 L across Plants 1-5 in Songdo and 60,000 L at Rockville, with Plants 1-4 at full utilisation. The second bio campus is planned with Plants 6-8 at 180,000 L each, taking antibody capacity to 1,385,000 L once complete; land has been secured for a third bio campus focused on emerging modalities. Commercially, the company opened a sales office in the Netherlands this quarter to strengthen local engagement with European clients.

A KRW 3T rights offering and PolyPeptide: peptides are the next card

Two capital actions are running in parallel. The public tender offer for Switzerland's PolyPeptide Group has met its acceptance condition with an 87.92% participation rate against a 66.7% threshold, extending the service portfolio from antibodies and conjugates into peptide-based therapeutics and adding PolyPeptide's manufacturing network across Europe, the United States and India. Separately, Samsung Biologics announced a KRW 3T rights offering to fund the acquisition and future capacity expansion, with existing shareholder subscriptions in November followed by a public offering of unsubscribed shares. The company also received an A rating in the latest MSCI ESG assessment and established a greenhouse gas emissions calculation system.

Read against the 2026 industry backdrop, the significance of this quarter is not the growth rate but the direction of margin. For two years the Samsung narrative was 'number one in capacity, full utilisation, pricing power'; 2026 is the phase of trading margin for share, with new plant ramps, overseas consolidation and integration costs all consuming margin simultaneously. Contrast Lonza, which on 14 October raised its mid-term CORE EBITDA margin ambition to the high thirties while keeping capex at a mid-to-high teens percentage of sales: the two leaders are now on opposite margin trajectories — Lonza pushing margin up inside a pure-play CDMO model, Samsung letting margin normalise as it scales. At 42.9% the current margin still sits above Lonza's mid-term target range, but the trend matters more: once depreciation on Plants 6-8 lands in 2027-2028, price elasticity becomes the next variable in order allocation.

Three things to watch: whether the three-week general strike originally set for 26 October actually goes ahead — the Seoul High Court expanded its injunction to nine core drug-substance processes at Songdo on 16 October, and the union has postponed while appealing without withdrawing; whether new contracts for Rockville's remaining capacity are signed this year; and how much the KRW 3T rights offering dilutes per-share metrics.